Recursion extended its winning streak to a fourth day on Wednesday, jumping 6.81 percent to close at $4.86 apiece as ...

Recursion Pharmaceuticals（纳斯达克股票代码：RXRX） 董事Christopher Gibson于2026年1月5日以每股4.25美元的价格出售了4万股A类普通股，总计17万美元。根据 InvestingPro 数据显示，该交易发生之际，该公司股票在过去一周内价格大幅上涨了18.83%，目前股价为4.86美元。

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

Recursion使用人工智能驱动的模型来识别和设计新的疗法，并将这些模型提供给其他制药商，包括罗氏和拜耳。总部位于犹他州盐湖城的Recursion将利用其超过23,000 tb的生物和化学数据集，在英伟达的云平台上训练其人工智能模型。

根据提交给美国证券交易委员会的Form 4文件显示， RECURSION PHARMACEUTICALS, INC.（纳斯达克股票代码：RXRX） 首席财务官Ben R. Taylor于2025年12月29日以每股4.18美元的价格出售了21,383股A类普通股。此次交易总价值为89,380美元。

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...